Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
David Montani (Le Kremlin-Bicêtre, France). Perspectives of therapeutic innovation from current progress in the pathobiology of pulmonary hypertension. ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease

Member's Comments

No comment yet.

Related content which might interest you: Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives Source: Eur Respir J, 53 (1) 1801887; 10.1183/13993003.01887-2018 Year: 2019 Idiopathic pulmonary fibrosis: current challenges and future perspectives Source: Eur Respir Rev 2013; 22: 103-105 Year: 2013 Clinical implications of the new concepts regarding COPD pathophysiology Source: Annual Congress 2008 - New insights into COPD pathophysiology Year: 2008 The definition of pulmonary hypertension: history, practical implications and current controversies Source: Breathe, 17 (3) 210076; 10.1183/20734735.0076-2021 Year: 2021 Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 253-262 Year: 2015 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Genetic testing in pulmonary hypertension: how should our clinical practice reflect recent advances? Source: Eur Respir J 2016; 47: 388-389 Year: 2016 The emerging role of epigenetics in pulmonary hypertension Source: Eur Respir J 2016; 48: 903-917 Year: 2016 Contemporary issues in pulmonary hypertension Source: Eur Respir Rev 2010 19: 266-271 Year: 2010 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 The importance of patient perspectives in pulmonary hypertension Source: Eur Respir J, 53 (1) 1801919; 10.1183/13993003.01919-2018 Year: 2019 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications Source: Eur Respir J 2010; 35: 418-425 Year: 2010 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 Advances in the therapeutical management of IPF Source: Annual Congress 2012 - MS3 Update in idiopatic pulmonary fibrosis Year: 2012 Translational research in pulmonary hypertension: challenge and opportunity Source: Eur Respir J 2014; 43: 325-328 Year: 2013 Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance? Source: Eur Respir J, 55 (6) 2000811; 10.1183/13993003.00811-2020 Year: 2020 Novel techniques for advancing our understanding of pulmonary arterial hypertension Source: Eur Respir J, 53 (5) 1900556; 10.1183/13993003.00556-2019 Year: 2019 Pulmonary arterial hypertension: tailoring treatment to risk in the current era Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017 Year: 2017